FDA warned drug repackager Safecor Health over CGMP failures that let tablets from other drugs contaminate packaging lines.
What happened
FDA inspected Safecor Health's Woburn, Massachusetts drug manufacturing and repackaging facility from March 7 to 16, 2023. Investigators found various capsules and tablets on and under a blister packaging machine while it was packing 81 mg chewable aspirin, even though batch records said the line had been cleared. They also found white powder residue on supposedly clean equipment, untested water used as a drug ingredient, and uncontrolled paper records, including torn and partly filled batch records and correction fluid used on a cleaning log.
What FDA found
The company did not properly check the packaging line before each run, so tablets and capsules from earlier drugs were left on and under the machine during an aspirin run.
21 CFR 211.130(e)Cleaning and maintenance procedures for equipment were not adequate, with unidentified white powder left on surfaces called clean and a cleaning requalification that picked drugs at random without scientific reason.
21 CFR 211.67(b)The company used purchased water as a drug ingredient but only looked at it, without testing it for identity, purity, strength or microbes.
21 CFR 211.84(d)(2)The quality unit did not control paper records: partly completed and torn-up manufacturing records, loose printed forms near the repackaging area, forms printable by many employees, and correction fluid used on a cleaning log.
21 CFR 211.22
What FDA wants
FDA tells the company to correct the violations promptly and to send a written response, including detailed evaluations and corrective action plans, by September 26, 2023. FDA also recommends hiring a qualified CGMP consultant to audit the whole operation.
Who should pay attention
- hospital and long-term care pharmacies that buy unit-dose repackaged drugs
- brands and pharmacies that contract with repackagers
- companies whose products are repackaged by third parties
This is a summary. Read the original letter on fda.gov.